Volume 13, Issue 3 (Autumn 2016)                   bloodj 2016, 13(3): 224-232 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Kazemzadeh S, Farsinejad A, Sabour Takanlu J, Kaviani S, Atashi A, Soleimani M et al . miR-146a: A possible tumor suppressor in multiple myeloma. bloodj 2016; 13 (3) :224-232
URL: http://bloodjournal.ir/article-1-1014-en.html
miR-146a: A possible tumor suppressor in multiple myeloma
Sh. Kazemzadeh , A.R. Farsinejad , J. Sabour Takanlu , S. Kaviani * , A. Atashi , M. Soleimani , S. Abroun
Keywords: Key words: Multiple Myeloma, MicroRNAs, miR-146a٬ human
Full-Text [PDF 552 kb]   (1919 Downloads)     |   Abstract (HTML)  (7173 Views)
Full-Text:   (2130 Views)
References:
 
  1. de Mel S, Lim SH, Tung ML, Chng WJ. Implications of heterogeneity in multiple myeloma. Biomed Res Int 2014; 2014: 232546.
  2. Gutiérrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, De Las Rivas J, Ticona F, et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 2010; 24(3): 629-37.
  3. Ocio E, Richardson P, Rajkumar S, Palumbo A, Mateos M, Orlowski R, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2014; 28(3): 525-42.
  4. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6(11): 857-66.
  5. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A 2004; 101(32): 11755-60.
  6. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005; 102(39): 13944-9.
  7. Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk PJ, Löwenberg B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008; 111(10): 5078-85.
  8. Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT, et al. Distinct microRNA expression profiles in acute myeloid  leukemia  with  common  translocations. Proc
Natl Acad Sci U S A 2008; 105(40): 15535-40.
  1. Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A 2008; 105(10): 3945-50.
  2. Visone R, Rassenti LZ, Veronese A, Taccioli C, Costinean S, Aguda BD, et al. Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood 2009; 114(18): 3872-9.
  3. Marcucci G, Radmacher MD, Maharry K, Mrózek K, Ruppert AS, Paschka P, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358(18): 1919-28.
  4. Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009; 113(26): 6669-80.
  5. Suzuki Y, Kim HW, Ashraf M, Haider HK. Diazoxide potentiates mesenchymal stem cell survival via NF-κB-dependent miR-146a expression by targeting Fas. Am J Physiol Heart Circ Physiol 2010; 299(4): H1077-82.
  6. Yuan Y, Kasar S, Underbayev C, Prakash S, Raveche E. MicroRNAs in Acute Myeloid Leukemia and Other Blood Disorders. Leuk Res Treatment 2012; 2012: 603830.
  7. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6(4): 259-69.
  8. Ebert MS, Sharp PA. Roles for microRNAs in conferring robustness to biological processes. Cell 2012; 149(3): 515-24.
  9. Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 2010; 42(8): 1273-81.
  10. Omrane I, Kourda N, Stambouli N, Privat M, Medimegh I, Arfaoui A, et al. MicroRNAs 146a and 147b biomarkers for colorectal tumor’s localization. Biomed Res Int 2014; 2014: 584852.
  11. Hasani SS, Hashemi M, Eskandari-Nasab E, Naderi M, Omrani M, Sheybani-Nasab M. A functional
    polymorphism in the miR-146a gene is associated with the risk of childhood acute lymphoblastic leukemia: a preliminary report. Tumour Biol 2014; 35(1): 219-25.
  12. Boldin MP, Taganov KD, Rao DS, Yang L, Zhao JL, Kalwani M, et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med 2011; 208(6): 1189-201.
  13. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111(5): 2516-20.
  14. Huang Y, Shen XJ, Zou Q, Wang SP, Tang SM, Zhang GZ. Biological functions of microRNAs: a review. J Physiol Biochem 2011; 67(1): 129-39.
  15. Sun CY, She XM, Qin Y, Chu ZB, Chen L, Ai LS, et al. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. Carcinogenesis 2013: 34(2): 426-35.
  16. Starczynowski DT, Morin R, McPherson A, Lam J, Chari R, Wegrzyn J, et al. Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations. Blood 2011; 117(2): 595-607.
  17. Liu R, Liu C, Chen D, Yang WH, Liu X, Liu CG, et al. Foxp3 controls an miR-146/NF-κB negative feedback loop that inhibits apoptosis in breast cancer cells. Cancer Res 2015; 75(8): 1703-13.
  18. Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res 2009; 69(4): 1279-83.
  19. Xiao B, Zhu ED, Li N, Lu DS, Li W, Li BS, et al. Increased miR-146a in gastric cancer directly targets SMAD4 and is involved in modulating cell proliferation and apoptosis. Oncol Rep 2012; 27(2): 559-66.
  20. Zhong H, Wang HR, Yang S, Zhong JH, Wang T, Wang C, et al. Targeting Smad4 links microRNA-146a to the TGF-β pathway during retinoid acid induction in acute promyelocytic leukemia cell line. Int J Hematol 2010; 92(1): 129-35.
 
 
 



 
 
 
 
Sci J Iran Blood Transfus Organ 2016; 13(3): 224-232
 
Original Article
 
 

miR-146a: A possible tumor suppressor
in multiple myeloma
 
Kazemzadeh S.1, Farsinejad A.2, Sabour Takanlu J.1, Kaviani S.1, Atashi A.3,
Soleimani M.1, Abroun S.1
 
 
 
1Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
2Kerman University of Medical Sciences, Kerman, Iran
3School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran
 
 
 
Abstract
Background and Objectives
MicroRNAs play a crucial role in controlling the innate and adaptive immune responses, inflammation, cell growth, and apoptosis by regulating gene expression at post-transcriptional level. In addition, many microRNAs act as oncogenes, tumor suppressors, and the mediators of cancer stem cells. MiR-146a is one of the important microRNAs in inflammatory diseases and tumors which has a dual effect on cancers and acts as a tumor promoter or a tumor suppressor. The present study aimed to evaluate the expression of miR-146a in multiple myeloma cell lines (L363, LP1, RPMI 8226 and KMM1) in comparison with normal leukocytes.
 
Materials and Methods
In this experimental study, four myeloma cell lines and peripheral blood leukocytes isolated from healthy individuals were cultured under specific conditions. After RNA extraction, miR-146a expression was measured by quantitative Real Time PCR.
 
Results
The research results showed that the expression of miR-146a in multiple myeloma cell lines was significantly decreased compared with normal leukocytes. Data analysis also revealed that the expression of miR-146a was decreased in average of 0.32 ± 0.2 folds in L363 cell line and for LP1, RPMI 8226, and KMM1 cell lines in average of 0.03 ± 0.07, 0.0035 ± 0.02, 0.0022±0.001 folds, respectively (p < 0.01).
 
Conclusions 
The researchers' results suggest that miR-146a can act as a tumor suppressor in leukocytes, and the decreased expression of this microRNA in myeloma cells is likely to be effective at the onset and progression of multiple myeloma.
 
Key words: Multiple Myeloma, MicroRNAs, miR-146a٬ human
 
 
Received: 4 Jan 2016
Accepted: 1 Jun 2016
 
 
 

Correspondence: Kaviani S., PhD of Hematology. Associate Professor of Faculty of Medical Sciences, Tarbiat
Modares University.
P.O.Box: 14115-331, Tehran, Iran. Tel: (+9821) 82883832; Fax: (+9821) 82884507.
E-mail:
 kavianis@modares.ac.ir
Type of Study: Research | Subject: Hematology
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Journal of Iranian Blood Transfusion

Designed & Developed by: Yektaweb